NasdaqGM:RYTMBiotechs
Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next
Rhythm Pharmaceuticals recently received a positive opinion from the European Medicines Agency’s CHMP to expand IMCIVREE’s authorization to acquired hypothalamic obesity, and appointed veteran life sciences leader Kim Popovits to its Board, succeeding Ed Mathers.
This combination of potential European label expansion for IMCIVREE and added commercialization expertise on the Board may meaningfully influence how Rhythm executes its rare neuroendocrine disease focus.
Next, we’ll examine how the...